NL-OMON28584招募中不适用
Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvement.
eiden University Medical Center (LUMC)0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Allo-SCT patient with a sibling or unrelated stem cell donor matched for at least HLA-A, -B, -C, and –DR alleles (8/8);
- •2. Age 18-75 years;
排除标准
- •1. Life expectation < 3 months;
- •2. End stage irreversible multi-system organ failure;
研究者
相似试验
进行中（未招募）
不适用
Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementpersistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementEUCTR2012-003691-40-NLeiden University Medical Center
已完成
2 期
Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementleukemialymfomen10024324lymphomaNL-OMON37016eids Universitair Medisch Centrum4
招募中
1 期
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AMLLeukemia, Myeloid, AcuteNCT05945849University of Pennsylvania16
招募中
1 期
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 AntigenT-cell Acute Lymphoblastic LymphomaT-non-Hodgkin LymphomaT-cell Acute Lymphoblastic LeukemiaNCT03081910Baylor College of Medicine54
终止
1 期
Allo CART-19 ProtocolAcute Lymphocytic LeukemiaNCT01551043University of Pennsylvania2